These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 35093506

  • 1. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
    Keruakous AR, Asch A, Aljumaily R, Zhao D, Yuen C.
    Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
    [Abstract] [Full Text] [Related]

  • 2. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
    Tao Y, Jin S, Yang D, Pan M, Ouyang W, Liu Y, Wang Y, Zhang W, Mi J.
    BMC Cancer; 2024 Apr 02; 24(1):406. PubMed ID: 38565996
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
    Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA.
    Transplant Cell Ther; 2022 Nov 02; 28(11):760.e1-760.e5. PubMed ID: 35940527
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
    Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, Usmani SZ.
    Biol Blood Marrow Transplant; 2019 Mar 02; 25(3):459-465. PubMed ID: 30481597
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
    Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, Murata R, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S.
    Ann Oncol; 2017 Oct 01; 28(10):2503-2510. PubMed ID: 28945825
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
    Belotti A, Ribolla R, Cancelli V, Villanacci A, Angelini V, Chiarini M, Giustini V, Facchetti GV, Roccaro AM, Ferrari S, Peli A, Bottelli C, Cattaneo C, Crippa C, Micilotta M, Frittoli B, Grazioli L, Rossi G, Tucci A.
    Cancer Med; 2021 Sep 01; 10(17):5859-5865. PubMed ID: 34263564
    [Abstract] [Full Text] [Related]

  • 12. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
    Fan H, Wang W, Zhang Y, Wang J, Cheng T, Qiu L, Wang X, Xia Z, An G.
    Cancer Biol Med; 2023 Jan 12; 20(1):77-87. PubMed ID: 36647781
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
    Nahi H, Afram G, Uttervall K, Lockmer S, Tätting L, Gahrton G, Kashif M, Alici E, Stromberg O, Klimkowska M, Lund J.
    Cancer Med; 2023 Nov 12; 12(22):20736-20744. PubMed ID: 37921243
    [Abstract] [Full Text] [Related]

  • 15. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
    Coffey DG, Osman K, Aleman A, Bekri S, Kats S, Dhadwal A, Catamero D, Kim-Schulze S, Gnjatic S, Chari A, Parekh S, Jagannath S, Cho HJ.
    J Immunother Cancer; 2024 Apr 12; 12(4):. PubMed ID: 38609316
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
    Shen LJ, Zhuansun SY, Ni BW, Zhang MY, Lu SS, Hua YN, Xiao D, Huang HH, Han XF, Zhong L, Zhong H, Wang T, Hou J.
    Zhonghua Yi Xue Za Zhi; 2022 Sep 27; 102(36):2861-2867. PubMed ID: 36153871
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].
    Yao WQ, Zhu MQ, Yan LZ, Jin S, Shang JJ, Yao Y, Yan S, Liu Y, Wu DP, Fu CC.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep 14; 40(9):720-725. PubMed ID: 31648471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.